MARKET

AKTX

AKTX

Akari
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.200
-0.040
-1.79%
Closed 16:19 07/06 EDT
OPEN
2.270
PREV CLOSE
2.240
HIGH
2.280
LOW
2.110
VOLUME
313.97K
TURNOVER
--
52 WEEK HIGH
3.350
52 WEEK LOW
0.8700
MARKET CAP
63.20M
P/E (TTM)
-2.4719
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AKTX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.

EPS

AKTX News

More
Akari Therapeutics 13G Filing From Aspire Capital Shows 19.89% Stake
Benzinga · 4d ago
Akari Therapeutics receives $30M capital commitment
Seeking Alpha - Article · 5d ago
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC
GlobeNewswire · 5d ago
Akari Therapeutics Announces Appointment of Chief Financial Officer
GlobeNewswire · 5d ago
Akari Therapeutics Enters Into Securities Purchase Agreement For Up To $30M With Aspire Capital Fund
Benzinga · 5d ago
Akari Therapeutics Announces Appointment Of Chief Financial Officer
Benzinga · 5d ago
3 Under-the-Radar Penny Stocks Gearing up for Gains
TipRanks · 06/25 16:23
Akari Therapeutics: An Investment Assessment
Seeking Alpha - Article · 06/16 07:09

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About AKTX

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4, or LTB4. It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement.
More

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.